Evidence map›Paper›PMID 42855583›Full record

ArticleEuropean journal of human genetics : EJHG2026

Characterisation of a Portuguese origin founder missense variant in MSH6.

Kenzie Melvill, Leora Witkowski, Céline Domecq, Nancy Hamel, Justin Mayers, Sofia Maia, Manuel R Teixeira, Carla Pinto, Inês Francisco, Cristina Albuquerque and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kenzie MelvillDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0009-0001-1547-7480
Leora WitkowskiDepartment of Human Genetics, McGill University, Montreal, QC, Canada.
Céline DomecqCancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Nancy HamelCancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Justin MayersPathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
Sofia MaiaMedical Genetics Department, Hospital Pediátrico de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Manuel R TeixeiraCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.ORCID http://orcid.org/0000-0002-4896-5982
Carla PintoDepartment of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Inês FranciscoUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-0214-5524
Cristina AlbuquerqueUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-9707-0317
Léa Guerrini-RousseauDepartment of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Olivia C TanCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Kevin McDonnellCity of Hope National Medical Center, Duarte, CA, USA.
Alexandra CapassoCity of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0009-0008-0882-0640
George ChongDepartment of Human Genetics, McGill University, Montreal, QC, Canada.
Victoria MarcusDepartment of Pathology, McGill University Health Centre, Montréal, QC, Canada.
William D FoulkesDepartment of Human Genetics, McGill University, Montreal, QC, Canada. william.foulkes@mcgill.ca.ORCID http://orcid.org/0000-0001-7427-4651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In certain populations, founder pathogenic variants are a common cause of Lynch syndrome. Here, we report the identification of a novel Portuguese founder variant, NM_000179.3 (MSH6):c.2061 T > G (p.Cys687Trp). Our study examined 14 probands and 19 additional family members who carry this variant. With one exception, haplotype data are consistent with a single origin for all heterozygotes, likely in the Leiria District of Portugal. We investigated the clinicopathological consequences of this variant and found that, as previously reported for MSH6 pathogenic variants, (a) the presence of a pathogenic variant is not reliably associated with loss of MSH6 expression or microsatellite instability and (b) endometrial cancer is the most common associated phenotype. Due to the requirement to apply the BP5 code according to ACMG criteria, the variant is classified as a variant of uncertain significance rather than likely pathogenic. Nevertheless, the balance of evidence we present here suggests that this variant is associated with an increased risk for MSH6-related Lynch syndrome tumors.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.